Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02234115 |
|
Recruitment Status :
Completed
First Posted : September 9, 2014
Results First Posted : April 13, 2018
Last Update Posted : March 5, 2019
|
Sponsor:
Foresee Pharmaceuticals Co., Ltd.
Information provided by (Responsible Party):
Foresee Pharmaceuticals Co., Ltd.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prostatic Neoplasms | Drug: Leuprolide Mesylate | Phase 3 |
This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was established to provide a vanguard of the first 30 subjects who will have more frequent monitoring of their safety. If safety is established, the remainder of the subjects will be entered into the clinical study (i.e., Part II). All subjects will be males with advanced prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 137 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma |
| Study Start Date : | August 2014 |
| Actual Primary Completion Date : | August 30, 2016 |
| Actual Study Completion Date : | January 5, 2017 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Prostate cancer
MedlinePlus related topics:
Prostate Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Leuprolide Mesylate 50mg
All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
|
Drug: Leuprolide Mesylate
Subcutaneous injection of 50mg Leuprolide Mesylate |
Primary Outcome Measures :
- Efficacy of Leuprolide Mesylate (LMIS 50mg) [ Time Frame: baseline to 28 days, 28 days to 336 days ]The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) following the first injection of LMIS 50 mg from Day 28 through Day 336 (remaining duration of the study).
Secondary Outcome Measures :
- Number of Participants With Adverse Events (AEs) [ Time Frame: 336 days ]Safety analysis was based on the safety information from the laboratory evaluations, AEs, and SAEs.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males aged ≥ 18 years old
- Males with histologically confirmed carcinoma of the prostate
- Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy
- Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit
- Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2
- Life expectancy of at least 18 months
-
Laboratory values
- Absolute neutrophil count ≥ 1,500 cells/µL
- Platelets ≥ 100,000 cells/µL
- Hemoglobin ≥ 10 gm/dL
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- AST (SGOT) ≤ 2.5 × ULN
- ALT (SGPT) ≤ 2.5 × ULN
- Serum creatinine ≤ 1.5 mg/dL
- Lipid profile within acceptable range according to investigator's judgment
- HgbA1c within acceptable range according to investigator's judgment
- Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
- Serum glucose within acceptable range according to investigator's judgement
- Urinalysis within normal range according to the investigator's judgment
- Agree to use male contraceptive methods during study trial
- Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
- All aspects of the protocol explained and written informed consent obtained
Exclusion Criteria:
- Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
- Receipt of any vaccination (including influenza) within 4 weeks of Baseline
- History of blood donation within 2 months of Baseline
- History of anaphylaxis to any LH-RH analogues
- Receipt of any LHRH suppressive therapy within 6 months of Baseline
- Major surgery, including any prostatic surgery, within 4 weeks of Baseline
- History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases. Subjects at risk for spinal cord compression will be excluded.
- Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
- History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
- History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
- Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator
- History of drug and/or alcohol abuse within 6 months of Baseline
- Contraindication to leuprolide or an LHRH agonist as indicated on package labeling
- Use of 5-alpha reductase inhibitor within the last 6 months of Baseline
- History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed
- Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens
- Use of any investigational agent within 4 weeks of Baseline
- Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for those listed in the permitted Concomitant Treatment section.
- Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02234115
Locations
Show 29 study locations
Sponsors and Collaborators
Foresee Pharmaceuticals Co., Ltd.
Investigators
| Study Director: | John Mao, PhD | Foresee Pharmaceuticals Co., Ltd. |
| Responsible Party: | Foresee Pharmaceuticals Co., Ltd. |
| ClinicalTrials.gov Identifier: | NCT02234115 |
| Other Study ID Numbers: |
FP01C-13-001 2013-001790-25 ( EudraCT Number ) |
| First Posted: | September 9, 2014 Key Record Dates |
| Results First Posted: | April 13, 2018 |
| Last Update Posted: | March 5, 2019 |
| Last Verified: | February 2019 |
Keywords provided by Foresee Pharmaceuticals Co., Ltd.:
|
Prostate Neoplasm Cancer Carcinoma |
Additional relevant MeSH terms:
|
Carcinoma Prostatic Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Prostatic Diseases Leuprolide Fertility Agents, Female Fertility Agents Reproductive Control Agents Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents |